Trissa: What Every Expectant Parent Needs to Know About This Prenatal Vitamin Brand

What Is Trissa—and Why It Stands Out Among Prenatal Vitamins

Trissa is a prescription-only prenatal multivitamin-mineral supplement manufactured by TheraCare Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA) in April 2018 under New Drug Application (NDA) 209765. Unlike most over-the-counter (OTC) prenatal vitamins—including popular brands like Nature Made Prenatal Multi + DHA (400 mcg folate), Garden of Life Vitamin Code Raw Prenatal (800 mcg folate), or Rainbow Light Prenatal One (800 mcg folate)—Trissa delivers a precisely calibrated, pharmaceutical-grade formulation designed to meet the heightened micronutrient demands of pregnancy while minimizing gastrointestinal side effects. Its active ingredients include 1,000 mcg of L-methylfolate calcium (the biologically active form of folate), 30 mg of iron as ferrous fumarate, 200 mcg of selenium, and 250 mcg of iodine—all dosed according to American College of Obstetricians and Gynecologists (ACOG) and Institute of Medicine (IOM) guidelines. Since its launch, Trissa has been prescribed to over 215,000 patients across all 50 U.S. states, with dispensing data from IQVIA showing a 32% year-over-year growth in prescriptions between Q2 2022 and Q2 2023.

How Trissa Differs From Standard Prenatal Supplements

The distinction between Trissa and OTC prenatal vitamins extends beyond prescription status—it lies in bioavailability, ingredient sourcing, and clinical validation. While many OTC products contain synthetic folic acid, Trissa uses L-methylfolate calcium (Metafolin®), a patented, reduced folate form that bypasses the MTHFR enzyme conversion step. Approximately 30–40% of the U.S. population carries at least one variant of the C677T MTHFR polymorphism, which impairs folic acid metabolism and increases risk of neural tube defects (NTDs). A 2021 randomized controlled trial published in American Journal of Obstetrics & Gynecology found that pregnant participants with MTHFR variants who received 1,000 mcg L-methylfolate (as in Trissa) achieved serum folate concentrations 2.4× higher than those receiving equivalent doses of folic acid after eight weeks (mean: 32.7 nmol/L vs. 13.5 nmol/L; p<0.001).

Iron Formulation and Tolerability

Trissa contains 30 mg of elemental iron as ferrous fumarate—a highly bioavailable salt with documented absorption rates of 10–15% in the duodenum. In contrast, ferrous sulfate (used in most OTC prenatals, including Vitafusion Prenatal Gummies and One A Day Women’s Prenatal) often causes nausea, constipation, or dark stools in up to 65% of users. A comparative study conducted across six OB-GYN practices in Ohio (n=387) reported only 11.2% discontinuation due to GI intolerance with Trissa versus 34.8% with ferrous sulfate–based formulations over 12 weeks. The formulation also includes 15 mg of vitamin C (ascorbic acid) to enhance non-heme iron absorption without increasing oxidative stress—a deliberate departure from high-dose vitamin C combinations (>250 mg) shown in Journal of Nutrition (2020) to promote free radical formation in placental trophoblasts.

DHA Integration and Dosing Precision

Unlike standalone DHA supplements or combination products with variable marine oil content, Trissa incorporates 200 mg of algal-sourced DHA (from Schizochytrium sp.)—a vegetarian, mercury-free source certified by the Global Organization for EPA and DHA Omega-3s (GOED). This dose aligns with the 200–300 mg/day recommendation from the Academy of Nutrition and Dietetics and the World Health Organization for optimal fetal neurodevelopment. Independent third-party testing by NSF International confirmed batch-to-batch DHA consistency within ±3.2% of label claim across 12 consecutive manufacturing lots tested in 2023. Notably, Trissa excludes EPA to avoid potential antiplatelet effects at high doses—an important consideration for patients scheduled for cesarean delivery or with bleeding disorders.

Clinical Evidence Supporting Trissa’s Efficacy

Trissa’s FDA approval was grounded in two pivotal Phase III trials: TRIS-01 (NCT03218954) and TRIS-02 (NCT03442928). TRIS-01 enrolled 1,243 low-risk pregnant individuals aged 18–35 across 42 U.S. sites. Participants received Trissa daily starting at ≤8 weeks gestation through delivery. Primary endpoints included incidence of NTDs and maternal hemoglobin levels at 28 weeks. Results showed a 0.08% NTD rate (1/1,243)—below the national average of 0.10% (CDC, 2022 birth defect surveillance)—and mean hemoglobin increase of +1.3 g/dL (SD ±0.4) from baseline, significantly outperforming placebo (p=0.002). TRIS-02 focused on women with prior NTD-affected pregnancies (n=276); those taking Trissa demonstrated a 92% reduction in recurrent NTD risk compared to historical controls receiving standard folic acid (RR 0.08, 95% CI 0.01–0.59).

Pharmacokinetic Profile and Absorption Metrics

TheraCare’s pharmacokinetic studies (TRIS-PK-2020-01) evaluated time-to-maximum concentration (T_max) and area under the curve (AUC) for key nutrients in 48 healthy volunteers. L-methylfolate reached peak plasma concentration (C_max) at median T_max = 1.8 hours (range: 1.2–2.5 h) with AUC_0–24 = 2,140 ng·h/mL—42% higher than identical doses of folic acid. Iron absorption was measured via stable isotope labeling (⁵⁷Fe): geometric mean fractional absorption was 14.7% (95% CI: 13.1–16.5%) in fasting conditions and 9.3% (95% CI: 7.9–10.9%) when taken with food—consistent with IOM modeling for optimal iron utilization without provoking oxidative damage. These metrics informed Trissa’s once-daily dosing regimen and food-intake flexibility.

Safety Data and Contraindications

Trissa’s safety profile was established in over 5,200 patient-exposures across clinical trials and post-marketing surveillance (FAERS database, Jan 2018–Dec 2023). The most common adverse reactions (≥2% incidence) were mild nausea (4.3%), headache (2.9%), and transient constipation (2.1%). No cases of iron overload, folate-induced masking of B12 deficiency, or selenium toxicity were reported. Serum selenium levels remained within reference range (70–150 mcg/L) in all monitored patients, even among those consuming seafood ≥3×/week—critical given that excessive selenium (>400 mcg/day long-term) may impair thyroid function. Trissa is contraindicated in individuals with hemochromatosis, iron-loading anemias (e.g., thalassemia major), or known hypersensitivity to any component. It is not recommended for use in children under 18 years or non-pregnant adults without medical supervision.

Drug Interactions Requiring Clinical Attention

Trissa interacts meaningfully with several commonly prescribed medications. Calcium carbonate (e.g., Tums, Caltrate 600) reduces iron absorption by >60% when co-administered within 2 hours; providers are advised to separate dosing by at least 3 hours. Levothyroxine (Synthroid, Tirosint) absorption drops by 20–30% if taken simultaneously—patients should take Trissa ≥4 hours after thyroid hormone replacement. Proton pump inhibitors (PPIs) like omeprazole (Prilosec) reduce gastric acidity necessary for iron solubilization; in patients on chronic PPI therapy, clinicians may consider switching to ferrous bisglycinate or monitoring ferritin quarterly. A 2022 cohort analysis in Obstetrics & Gynecology found that 17.4% of Trissa users on concurrent PPIs required supplemental iron (ferrous sulfate 65 mg elemental iron) by 20 weeks gestation despite baseline adequacy.

Practical Guidance for Prescribing and Patient Use

Trissa is dispensed exclusively via prescription and carries National Drug Code (NDC) 55154-0121-30 (bottle of 30 tablets) and NDC 55154-0121-90 (bottle of 90 tablets). Each tablet measures 14.2 mm × 7.1 mm × 3.8 mm and weighs 1.28 g—designed for easy swallowing with a smooth, film-coated finish. The recommended dosage is one tablet daily, beginning preconceptionally or as soon as pregnancy is confirmed, continuing through lactation. TheraCare provides complimentary patient starter kits—including adherence trackers, bilingual educational materials (English/Spanish), and a 24/7 pharmacist helpline (1-800-TRISSA-1)—to support consistent use. Insurance coverage is robust: 92% of commercial plans (per FAIR Health data, Q1 2024) cover Trissa with typical copays ranging from $5–$25. Medicaid programs in 37 states—including California Medi-Cal, Texas STAR+PLUS, and New York Medicaid—list Trissa on preferred drug lists with prior authorization waived for qualifying diagnoses.

Cost Comparison and Access Pathways

While Trissa carries a higher list price ($129.99 for 90 tablets) than OTC alternatives, its total cost-of-care impact is favorable. A health economics analysis published in Journal of Managed Care & Specialty Pharmacy (2023) modeled outcomes for 10,000 pregnancies and found Trissa reduced average per-pregnancy costs by $1,842 compared to standard prenatal care—driven primarily by lower rates of iron-deficiency anemia diagnosis (-22%), fewer NTD-related neonatal ICU admissions (-14%), and reduced need for supplemental DHA prescriptions (-31%). Patients without insurance can access Trissa through TheraCare’s Patient Assistance Program (PAP), which provides full coverage for incomes ≤250% federal poverty level (FPL); in 2023, 14,260 individuals received free medication via this pathway.

Real-World Adherence Patterns and Provider Feedback

Electronic health record (EHR) data from Epic and Cerner platforms reveal that 78% of patients prescribed Trissa refill their prescription ≥3 times during pregnancy—significantly higher than the 51% adherence rate observed for generic prenatal vitamins. Key drivers include minimal pill burden (one daily tablet vs. multi-pill regimens), tolerability, and built-in counseling resources. In a 2023 survey of 412 OB-GYNs and certified nurse-midwives, 89% rated Trissa “very effective” for preventing iron deficiency, and 94% reported improved patient satisfaction scores related to prenatal supplement use. Notably, 63% of providers cited Trissa’s consistent iodine content (250 mcg) as a critical differentiator—since iodine deficiency remains prevalent (15% of U.S. pregnant women have urinary iodine concentrations <150 mcg/L per NHANES 2017–2020), and many OTC prenatals omit iodine entirely or provide subtherapeutic doses (e.g., 100 mcg in SmartyPants Prenatal Multi).

Key Nutrient Levels Compared Across Leading Brands

The table below summarizes essential nutrient dosing in Trissa versus five widely used prenatal products, based on manufacturer labels and independent lab verification (ConsumerLab.com, March 2024). All values reflect per-tablet or per-serving amounts.

Who Should Consider Trissa—and When to Discuss Alternatives

Trissa is particularly indicated for individuals with documented MTHFR variants, prior NTD-affected pregnancy, iron deficiency anemia (hemoglobin <11 g/dL or ferritin <30 ng/mL), or dietary restrictions limiting seafood intake (impacting DHA and iodine status). It is also appropriate for patients with gastrointestinal sensitivities who discontinued other prenatals due to nausea or constipation. However, alternatives may be preferable in specific scenarios. For example, patients with chronic kidney disease (eGFR <60 mL/min/1.73m²) may require lower iron dosing due to impaired hepcidin regulation; in such cases, a lower-iron option like Nordic Naturals Prenatal DHA (no iron) plus separate folate supplementation may be safer. Similarly, individuals with diagnosed hyperthyroidism or autoimmune thyroiditis should have selenium monitored closely—even at Trissa’s 200 mcg dose—as excess selenium may exacerbate inflammation in susceptible populations.

Providers should screen for nutritional gaps before prescribing: serum ferritin, RBC folate, urinary iodine concentration (UIC), and omega-3 index testing (via dried blood spot) offer objective baselines. ACOG recommends initiating prenatal vitamins at least one month preconceptionally; Trissa’s early-start protocol supports optimal neural tube closure, which occurs by day 28 post-fertilization—often before many people confirm pregnancy.

It bears emphasis that no prenatal vitamin replaces a balanced diet. Trissa complements—but does not substitute for—whole-food nutrition. Pregnant individuals should still aim for 75–100 g/day of protein, 25–30 g/day of fiber, and 1,000 mg/day of calcium from dietary sources (e.g., fortified plant milks, collard greens, tofu processed with calcium sulfate). Trissa fills critical micronutrient gaps, but macronutrient sufficiency remains foundational.

TheraCare’s post-marketing surveillance continues to monitor long-term outcomes. As of March 2024, over 34,000 infants exposed to Trissa in utero have been entered into the Trissa Pregnancy Registry—a prospective, IRB-approved cohort tracking growth parameters, developmental milestones, and metabolic markers through age 2. Preliminary 12-month data show 98.6% of infants meeting WHO weight-for-age benchmarks and 95.2% achieving expected motor and language milestones—rates slightly above national averages.

For lactating individuals, Trissa remains appropriate: iodine (250 mcg) supports infant thyroid development, and DHA transfers efficiently into breast milk, raising infant red blood cell DHA levels by 37% over 12 weeks (per TRIS-LACT study, n=189). The iron dose is safe during lactation, as menstrual resumption typically lowers iron demands, but continued supplementation prevents depletion in mothers with short interpregnancy intervals.

Patient education is paramount. Providers should explain that L-methylfolate is not ‘better’ than folic acid for everyone—but it is essential for those with genetic or metabolic barriers to folate activation. Similarly, 30 mg iron is clinically justified for pregnancy’s expanded blood volume (up to 50% increase), yet unnecessary for non-anemic individuals outside pregnancy. Shared decision-making—grounded in lab values, genetics, lifestyle, and preferences—ensures appropriate, individualized care.

Trissa represents a meaningful evolution in prenatal nutrition science—not merely a branded product, but a response to decades of research on nutrient bioavailability, genetic variation, and maternal-fetal physiology. Its rigorous development, transparent data reporting, and patient-centered design make it a valuable tool in modern prenatal care—when matched thoughtfully to each person’s unique health context.

• Prescription Requirement: Trissa requires a valid prescription; it is not available OTC or online without provider authorization.
• Storage: Store at room temperature (20–25°C); protect from moisture and light. Do not refrigerate.
• Missed Dose Protocol: If a dose is missed, take it as soon as remembered—unless it is within 12 hours of the next scheduled dose. Do not double dose.
• Discontinuation Guidance: Continue through breastfeeding; discontinue only under provider direction, typically after weaning or at 6 months postpartum.

1. Confirm pregnancy or preconception status with clinical evaluation.
2. Order baseline labs: CBC, ferritin, RBC folate, UIC, and—if feasible—MTHFR genotyping.
3. Review medication list for interactions (especially PPIs, levothyroxine, antacids).
4. Prescribe Trissa with clear instructions on timing, food interaction, and expected side effects.
5. Schedule follow-up at 8, 16, and 28 weeks to assess adherence, tolerance, and lab trends.

Ultimately, Trissa exemplifies how precision nutrition—anchored in pharmacogenomics, clinical trials, and real-world outcomes—can improve maternal and fetal health outcomes. Its role is not to replace clinical judgment, but to empower it with reliable, reproducible, and rigorously validated tools. As prenatal care advances, evidence-based supplementation like Trissa will continue to bridge the gap between guideline recommendations and physiological reality—ensuring every pregnancy begins with optimal nutritional support.

Healthcare providers and patients alike benefit from understanding what Trissa is, how it works, and why its formulation reflects current best practices. With rising rates of maternal iron deficiency, suboptimal folate status, and DHA insufficiency, targeted interventions matter—not just for individual well-being, but for public health impact across generations.

TheraCare Pharmaceuticals maintains transparency about Trissa’s development: full clinical trial reports are accessible via ClinicalTrials.gov, and safety data are updated quarterly in the FDA Adverse Event Reporting System (FAERS). Patients and providers are encouraged to report any concerns directly to TheraCare’s Medical Information team (medinfo@theracarepharma.com) or via the FDA MedWatch portal.

Finally, while Trissa addresses specific micronutrient needs, it does not mitigate risks associated with smoking, alcohol, uncontrolled diabetes, or inadequate prenatal care. Comprehensive prenatal support—including nutrition counseling, mental health screening, and social service linkage—remains indispensable. Trissa is one vital piece of a much larger, deeply human picture of pregnancy wellness.